Craig-Hallum continues to recommend buying MiMedx Group as a good investment choice

MiMedx Group (MDXG) has recently disclosed insider trading activity in an SEC filing, shedding light on the internal sentiment within the company. The filing, dated July 3, 2025, detailed how Doug Rice, a director and Chief Financial Officer at MDXG, sold 12,749 shares of the company’s common stock on July 3, 2025, at a price of $6.34 per share. This transaction resulted in a reduction of Rice’s beneficial ownership to 188,024 shares.

Despite this insider sale, there is a prevailing positive market sentiment surrounding MDXG. Analyst Chase Knickerbocker from Craig-Hallum maintains a Buy rating for the company, setting a price target of $11.75. The consensus rating for MDXG is Strong Buy, and the stock has reached a one-year high of $10.14. Notably, over the past quarter, 27 insiders at MDXG have purchased shares, pointing to an optimistic stance within the company.

As a 4-star analyst with a track record, Knickerbocker boasts an average return rate of 9.2% and a success rate of 53.36%. His endorsement of MDXG’s growth opportunities aligns with the positive sentiment reflected by both insiders and analysts, potentially positioning MDXG as an appealing investment prospect for interested parties.